It's pretty unusual in the medical system for a patient to be tasked with finding their own cure. But that’s what happened to Stephanie Azzarello in 2023 when she was told she needed a liver ...

Achieving sustained virological response after direct-acting antiviral therapy reduces liver-related events among those with decompensated HCV cirrhosis.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline reprioritisation.